{"id":"riluzole-100-mg","safety":{"commonSideEffects":[{"rate":null,"effect":"Asthenia / fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Liver enzyme elevation"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL744","moleculeType":"Small molecule","molecularWeight":"234.20"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Riluzole is a neuroprotective agent that works through multiple mechanisms: it inhibits the presynaptic release of glutamate, blocks inactivated sodium channels, and may enhance GABA-mediated inhibitory neurotransmission. These actions reduce excitotoxic neuronal damage caused by excessive glutamate signaling, which is implicated in neurodegenerative diseases.","oneSentence":"Riluzole reduces glutamate excitotoxicity by inhibiting glutamate release and blocking sodium channels in neurons.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:32:13.322Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Amyotrophic lateral sclerosis (ALS)"},{"name":"Other neurodegenerative conditions (under investigation)"}]},"trialDetails":[{"nctId":"NCT07414212","phase":"PHASE1, PHASE2","title":"Evaluation of the Combined Therapy of EH-301 and N-acetylcysteine Together With Riluzole in Amyotrophic Lateral Sclerosis (ALS)","status":"RECRUITING","sponsor":"Biogipuzkoa Health Research Institute","startDate":"2025-11-25","conditions":"Amyotrophic Lateral Sclerosis","enrollment":90},{"nctId":"NCT07142291","phase":"PHASE2","title":"PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS","status":"RECRUITING","sponsor":"PhenoNet, Inc.","startDate":"2025-11-25","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":105},{"nctId":"NCT05508074","phase":"PHASE2","title":"Treatment Combining Riluzole and IFB-088 in Bulbar Amyotrophic Lateral Sclerosis (TRIALS Protocol)","status":"COMPLETED","sponsor":"InFlectis BioScience","startDate":"2022-12-02","conditions":"Amyotrophic Lateral Sclerosis, ALS","enrollment":51},{"nctId":"NCT07174492","phase":"PHASE3","title":"Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS Patients","status":"NOT_YET_RECRUITING","sponsor":"AB Science","startDate":"2026-01-01","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":412},{"nctId":"NCT06552260","phase":"EARLY_PHASE1","title":"A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma","status":"RECRUITING","sponsor":"Ugonma Chukwueke","startDate":"2025-02-19","conditions":"Glioblastoma, Recurrent Glioblastoma, Brain Tumor","enrollment":27},{"nctId":"NCT03660917","phase":"PHASE2, PHASE3","title":"Riluzole in Patients With Spinocerebellar Ataxia Type 7","status":"RECRUITING","sponsor":"S. Andrea Hospital","startDate":"2021-06-01","conditions":"SCA7","enrollment":34},{"nctId":"NCT01277315","phase":"PHASE2","title":"Safety and Tolerability of Anakinra in Combination With Riluzol in Amyotrophic Lateral Sclerosis","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2011-02","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":20},{"nctId":"NCT00866840","phase":"PHASE2","title":"Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"Rutgers, The State University of New Jersey","startDate":"2009-04","conditions":"Melanoma (Skin)","enrollment":13},{"nctId":"NCT04326283","phase":"PHASE1, PHASE2","title":"Trial of Safety, Tolerability and Efficacy of Trametinib (SNR1611) in Patients With Amyotrophic Lateral Sclerosis (ALS)","status":"TERMINATED","sponsor":"Genuv Inc.","startDate":"2020-04-02","conditions":"Amyotrophic Lateral Sclerosis","enrollment":23},{"nctId":"NCT02859792","phase":"PHASE2","title":"Riluzole in the Treatment of Spasticity in the Traumatic Chronic Spinal Cord Injury Condition","status":"UNKNOWN","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2019-05-27","conditions":"Spinal Cord Injury","enrollment":90},{"nctId":"NCT03693781","phase":"PHASE2","title":"Colchicine for Amyotrophic Lateral Sclerosis","status":"COMPLETED","sponsor":"Azienda Ospedaliero-Universitaria di Modena","startDate":"2019-04-10","conditions":"Amyotrophic Lateral Sclerosis","enrollment":54},{"nctId":"NCT02155829","phase":"PHASE1, PHASE2","title":"Safety Study of Riluzole to Treat Post-traumatic Stress Disorder (PTSD)","status":"COMPLETED","sponsor":"Uniformed Services University of the Health Sciences","startDate":"2013-07","conditions":"PTSD","enrollment":75},{"nctId":"NCT02796755","phase":"PHASE4","title":"Effects of Riluzole on CNS Glutamate and Fatigue in Breast Cancer Survivors With High Inflammation","status":"COMPLETED","sponsor":"Emory University","startDate":"2016-04","conditions":"Inflammation, Fatigue","enrollment":30},{"nctId":"NCT04630444","phase":"EARLY_PHASE1","title":"Riluzole Effects on Hippocampus Biomarkers","status":"COMPLETED","sponsor":"Mclean Hospital","startDate":"2017-03-16","conditions":"Posttraumatic Stress Disorder","enrollment":20},{"nctId":"NCT01703039","phase":"PHASE2","title":"Riluzole Augmentation Pilot in Depression (RAPID) Trial","status":"TERMINATED","sponsor":"Brigham and Women's Hospital","startDate":"2013-01","conditions":"Major Depressive Disorder","enrollment":21},{"nctId":"NCT00419003","phase":"PHASE4","title":"Research Study for Major Depressive Disorder: Investigation of Glutamate Medications","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2006-12","conditions":"Major Depression","enrollment":26},{"nctId":"NCT00544544","phase":"NA","title":"Riluzole in the Treatment of Bipolar Depression","status":"COMPLETED","sponsor":"Mclean Hospital","startDate":"2007-06","conditions":"Bipolar Depression","enrollment":14},{"nctId":"NCT00376220","phase":"PHASE2","title":"A Double-Blind Placebo Controlled Trial of Riluzole in Bipolar Depression","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2004-05","conditions":"Bipolar Disorder","enrollment":94},{"nctId":"NCT00903214","phase":"PHASE1","title":"Riluzole in Women With Stage I, Stage II, or Stage IIIA Breast Cancer","status":"WITHDRAWN","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2009-05","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT00231140","phase":"PHASE2","title":"Pilot-Study of Thalidomide in Amyotrophic Lateral Sclerosis (ALS)","status":"TERMINATED","sponsor":"Charite University, Berlin, Germany","startDate":"2005-12","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":32,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Yooritek","Rilutek"],"phase":"phase_3","status":"active","brandName":"Riluzole (100 mg)","genericName":"Riluzole (100 mg)","companyName":"AB Science","companyId":"ab-science","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Riluzole reduces glutamate excitotoxicity by inhibiting glutamate release and blocking sodium channels in neurons. Used for Amyotrophic lateral sclerosis (ALS), Other neurodegenerative conditions (under investigation).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}